Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
12 Feb 2016: My day of reckoning

"In the flash of an eye my 12 weeks on hepatitis C treatment was over, virtually without incident, and I was cured. And then the Australian Government announced that we would all have access, without any restriction based on treatment history, liver disease progression or substance use history. I am so grateful to have had access to this treatment before others who are in a similar position, but I am even more the pleased that 2016 will be the year that so many people in Australia and elsewhere are finally cured of hepatitis C."

Published
12 February 2016
From
Hep Magazine
Survival and outcome analysis shows that selected HIV-positive patients are good candidates for liver and kidney transplant

Liver and kidney transplant can be justified for carefully selected HIV-positive patients, researchers from the United States show in AIDS. Transplant improved the chances of survival for HIV-positive

Published
11 February 2016
By
Michael Carter
New Report and Monitoring Tool: HIV, HCV, TB and Harm Reduction in Prisons

A new report from Harm Reduction International identifies some of the most important human rights and public health standards relating to HIV, HCV and TB in prisons, and the vital role of harm reduction provision in ensuring them.

Published
10 February 2016
From
Harm Reduction International
Are States Obligated To Provide Expensive Hepatitis C Drugs?

A handful of federal lawsuits against states that have denied highly effective but costly hepatitis C drugs to Medicaid patients and prisoners could cost states hundreds of millions of dollars.

Published
10 February 2016
From
Kaiser Health News
New cases of hepatitis C in NYC are on the rise

An estimated 146,000 New Yorkers over the age of 20 — 2.4 percent of that population — have hepatitis C, according to a new report from the city's health department which provides fresh evidence that state spending on wonder drugs such as Sovaldi and Harvoni is likely to continue to swell in the coming years.

Published
09 February 2016
From
Politico
Johns Hopkins approved to perform first HIV-positive to HIV-positive organ transplants in U.S.

Johns Hopkins recently received approval from the United Network for Organ Sharing to be the first hospital in the United States to perform HIV-positive to HIV-positive organ transplants. The institution will be the first in the nation to do an HIV-positive kidney transplant and the first in the world to execute an HIV-positive liver transplant.

Published
09 February 2016
From
Johns Hopkins Medicine
mapCrowd: an online data collection platform for hepatitis C information

Médecins du Monde (MdM) and Treatment Action Group (TAG) are pleased to announce the launch of mapCrowd (www.mapCrowd.org), an innovative online resource and data collection platform for gathering and sharing hepatitis C information.

Published
09 February 2016
From
Treatment Action Group
Olysio/Sovaldi yield high SVR post-liver transplant

In a retrospective study, a combination treatment regimen of Olysio and Sovaldi led to high sustained virologic response rates among patients with hepatitis C virus infection post-liver transplant and with advanced liver disease.

Published
08 February 2016
From
Healio
Fair Pricing Coalition Recognizes Merck’s Lower Price for Curative Hepatitis C Treatment, Calls for Manufacturers to Reduce Excessive Prices and Increase Patient Assistance

The Fair Pricing Coalition (FPC) today expressed appreciation for Merck’s & Co. Inc.’s decision to launch its new curative hepatitis C (HCV) treatment, Zepatier, at a price below existing HCV treatments in a tacit acknowledgement that existing high prices have hurt patients and are untenable for the market. Zepatier’s $54,600 list price is lower than the egregious prices for Gilead Sciences’ Harvoni ($94,500) and AbbVie’s Viekira Pak ($83,319), and represents a step in the right direction.

Published
08 February 2016
From
Fair Pricing Coalition
U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C

Updated label provides new treatment option for patients with HIV-1 coinfection, advanced cirrhosis, and post-liver transplant HCV recurrence.

Published
08 February 2016
From
Bristol-Myers Squibb press release
← First12345...189Next →

Filter by country